All In Biotech

Drug Trial Radar · NCT02958046

The Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity

Phase 4 Study, Assessing the Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity

Last checked: Nov 20, 2026Latest source record: Nov 8, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Jan 2014

Primary completion

May 2015

Study completion Aug 2015

Sponsor

Lead sponsor
Neutec Ar-Ge San ve Tic A.ŞIndustry
Sponsor type
Industry
First posted
Nov 8, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the efficacy of lansoprazole combination with domperidone on intragastric acidity and intraesophageal acidity, GERD symptoms, impedance kinetics, gastric emptying in patients with gastroesophageal reflux disease (GERD).

Conditions

  • Gastroesophageal Reflux Disease

Interventions

  • Lansoprazole/DomperidoneDrug

    DUOLANS 30/30 mg SR tablet per oral, one tablet daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage time of 24-hour intragastric pH >4 compared to baselineTime frame: 7 days
  2. The AUC of 24-hour intragastric pH >4 compared to baselineTime frame: 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department Of Gastroenterology, Faculty Of Medicine, Ege University, Izmir, Turkey

    Izmir, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.